Vaginal Itching with Jardiance (Empagliflozin) and Metformin
Yes, vaginal itching is a well-established side effect of Jardiance (empagliflozin), occurring in 5.4-6.4% of women, while metformin does not cause this problem. The itching is caused by genital mycotic infections (vulvovaginal candidiasis) resulting from increased glucose in the urine, which creates an environment that promotes yeast overgrowth 1.
Understanding the Mechanism
Jardiance works by blocking glucose reabsorption in the kidneys, forcing excess glucose into the urine. This glycosuria creates an ideal breeding ground for Candida species in the vaginal area. The FDA label explicitly warns about this risk, noting that vaginal yeast infections are one of the most common side effects in women taking this medication 1.
In clinical trials, genital mycotic infections occurred in:
- 5.4% of women on Jardiance 10 mg
- 6.4% of women on Jardiance 25 mg
- Only 1.5% on placebo 1
Recent comparative data shows empagliflozin carries a slightly higher risk of genital infections than other SGLT2 inhibitors like dapagliflozin (2.2% vs 2.0%), though the absolute difference is small 2. When compared to sitagliptin (a different diabetes drug class), empagliflozin shows significantly higher rates of genital infections 3.
Management Approach
Treat the yeast infection with standard antifungal therapy while continuing Jardiance, unless infections become recurrent or severe 4, 5.
First-Line Treatment Options:
- Over-the-counter intravaginal azoles: Clotrimazole 1% cream (5g daily for 7-14 days) or miconazole 2% cream (5g daily for 3 days) 5
- Oral fluconazole: Single 150mg dose (prescription required)
Prevention Strategies:
- Maintain meticulous genital hygiene
- Keep the area dry
- Wear breathable cotton underwear
- Avoid tight-fitting clothing 1
When to Discontinue Jardiance:
Stop the medication if:
- Infections become chronic or recurrent despite treatment
- Patient develops necrotizing fasciitis (Fournier's gangrene) - rare but serious, presenting with pain, tenderness, redness, swelling of genitals with fever >100.4°F 1
- Patient has history of chronic recurrent yeast infections that worsen on therapy 4
Critical Clinical Considerations
The 2025 ADA guidelines acknowledge this risk but still recommend SGLT2 inhibitors like Jardiance as preferred agents for patients with cardiovascular disease, heart failure, or chronic kidney disease due to their substantial mortality benefits 4. The cardiovascular and renal protective effects typically outweigh the inconvenience of treatable genital infections in most patients.
High-risk patients who should avoid Jardiance include:
- Women with chronic recurrent vulvovaginal candidiasis
- Immunocompromised patients
- Those with poor genital hygiene access 4
Metformin's Role:
Metformin does not cause vaginal itching. Its main side effects are gastrointestinal (nausea, diarrhea), which can be mitigated with slow dose titration and extended-release formulations 4. If vaginal itching develops on this combination, Jardiance is the culprit.
Diagnostic Confirmation
Before attributing symptoms to Jardiance, confirm the diagnosis:
- Vaginal pH testing (normal <4.5 in candidiasis)
- Wet mount microscopy showing budding yeast or pseudohyphae
- Fungal culture if symptoms persist despite treatment 5
Other causes of vaginal itching in diabetic women include bacterial vaginosis, trichomoniasis, contact dermatitis, or genitourinary syndrome of menopause in postmenopausal women 6. Don't assume every case of itching is yeast without proper evaluation.
Bottom Line Algorithm
- Confirm yeast infection with appropriate testing
- Treat with standard antifungal therapy (topical or oral azole)
- Continue Jardiance if cardiovascular/renal benefits justify use
- Implement preventive hygiene measures
- Switch to alternative diabetes medication (GLP-1 agonist, DPP-4 inhibitor) only if infections become recurrent or unmanageable
The decision to continue Jardiance should weigh the proven 38% reduction in cardiovascular death and 35% reduction in heart failure hospitalization 7 against the manageable inconvenience of treatable yeast infections in most patients.